A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough
Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
This PHASE2 trial investigates Refractory Chronic Cough and is currently completed. Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jan 2024 [monthly]
Completed PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Feb 2019 — Jul 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
-
May 2017 — Mar 2018 [monthly]
Completed PHASE2
-
Feb 2017 — May 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.